VistaGen Receives Notice Of Allowance From U.S. Patent And Trademark Office For U.S. Patent Regarding Methods Of Production For AV-101
Published: Oct 02, 2017
SOUTH SAN FRANCISCO, CA --(Marketwired - September 28, 2017) - VistaGen Therapeutics Inc. (
"We are pleased that the USPTO has allowed this U.S. patent relating to production methods for AV-101 at this significant period in its clinical development. Together with other granted patents and pending patent applications, this new patent will enhance our exclusivity for AV-101," stated Shawn Singh, Chief Executive Officer of VistaGen. "We are also pleased that a corresponding patent application has been granted in China. Together with the Notice of Intention to Grant European Patent 2948140B1, which relates to treatment of depression with AV-101 and its use to reduce levodopa-induced dyskinesia associated with Parkinson's disease therapy, this Notice of Allowance in the U.S. is yet another important step forward, further strengthening and expanding our AV-101 IP portfolio."
VistaGen Therapeutics, Inc. (
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the successful launch, continuation and results of the NIMH's Phase 2 (monotherapy) and/or the Company's planned Phase 2 (adjunctive therapy) clinical studies of AV-101 in MDD, and other CNS diseases and disorders, including neuropathic pain and levadopa-induced dyskinesia associated with Parkinson's disease therapy, protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the AV-101 clinical development activities described above. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.